Could a drug cocktail boost survival in early oral cancer?
NCT ID NCT07267286
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This phase 2 trial tests whether adding the immunotherapy drug tirellizumab plus chemotherapy before standard surgery can improve outcomes for people with early oral squamous cell carcinoma. Sixty participants will be randomly assigned to either the drug combo plus surgery or surgery alone. The main goal is to see if the combo increases the number of patients who remain free of cancer-related events for two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun yat-sen memorial hospital
Guangzhou, Guangdong, 510000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirellizumab (a PD-1 inhibitor) combined with carboplatin and albumin-bound paclitaxel
What this could lead to
If it works, this could improve survival and reduce recurrence for people with early oral cancer, offering a more effective treatment option.
What could go wrong
This is a small, early-phase exploratory study with only 60 participants. The combination therapy may cause side effects like immune reactions or infections, and it may not prove better than standard surgery alone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.